Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 299, Issue 3, 2001, Pages 1073-1085

  Tille, J C ^a   Wood, J ^b   Mandriota, S J ^a   Schnell, C ^b   Ferrari, S ^b   Mestan, J ^b   Zhu, Z ^c   Witte, L ^c   Pepper, M S ^a,d  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ELI LILLY AND COMPANY   (United States)

^d University Medical Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AAC 789; AAD 777; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BLOCKING ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN G; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 2 RECEPTOR ANTAGONIST; VATALANIB;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL INVASION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOGLOBULIN G; LYMPHOKINES; NEOVASCULARIZATION, PHYSIOLOGIC; PHTHALAZINES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035204128     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
2. New anilino-phthalazones as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinase useful as antagonists of tumor driven angiogenesis
3. Vascular endothelial growth factor C induces angiogenesis in vivo
4. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
5. Role of vascular endothelial growth factor in regulation of physiological angiogenesis
6. SU5416 is apotent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-/KDR) that inhibits tyrosine kinase catalysis, tumor vascularizatien, and growth of multiple tumor types
7. Cultured endothelial cell monolayers that restrict the transendothelial passage of macromolecules and electrical current
8. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis
9. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
10. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
11. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
12. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
13. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
14. Vascular endothelial growth factor is a secreted antiogenic mitogen
15. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
16. Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells
17. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor
18. NVP-AAD777/ZK202664, a selective VEGF receptor kinase inhibitor, which inhibits both VEGF- and bFGF-induced angiogenesis
19. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
20. Tumor-promoting phorbol esters induce angiogenesis in vitro
21. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
22. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
23. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro
24. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells
25. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity
26. Angiogenesis-regulating cytokines: Activities and interactions
27. Coupling and connexin 43 expression in microvascular and large vessel endothelial cells
28. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
29. Upregulation of urokinase receptor expression on migrating endothelial cells
30. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
31. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis
32. DNA sequencing with chain-terminating inhibitors
33. Autocrine activities of basic fibroblast growth factor: Regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis
34. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis
35. Hypoxic induction of vascular endothelial growth factors in the retina: Identification and characterization of vascular endothelial growth factor (VEGF) as the sole mitogen
36. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
37. Regulation of angiogenesis via vascular endothelial growth factor receptors
38. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
39. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
40. PTK787/ZK 222584, a novel and potent inhibitor of VEGF receptor tyrosine kinases, impairs VEGF-induced responses and tumor growth after oral administration
41. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library